CORCEPT THERAPEUTICS INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
CORCEPT THERAPEUTICS INC (CORT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $30.67 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $30.67, a 25.59% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $24.42, a 15.41% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $21.16, a 2.89% decline from fiscal 2022.
- CORCEPT THERAPEUTICS INC share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $21.79, a 20.59% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $30.67 10-K · filed 2026-02-24 |
| 2024-12-31 | $24.42 10-K · filed 2025-02-26 |
| 2023-12-31 | $21.16 10-K · filed 2024-02-15 |
| 2022-12-31 | $21.79 10-K · filed 2023-02-28 |
| 2021-12-31 | $18.07 10-K · filed 2022-02-15 |
| 2020-12-31 | $13.11 10-K · filed 2021-02-23 |
| 2019-12-31 | $12.68 10-K · filed 2020-02-24 |
| 2018-12-31 | $11.08 10-K · filed 2020-02-24 |
| 2017-12-31 | $5.04 10-K · filed 2020-02-24 |
| 2016-12-31 | $3.98 10-K · filed 2019-02-26 |
| 2015-12-31 | $3.07 10-K · filed 2018-02-28 |
| 2014-12-31 | $5.03 10-K · filed 2017-03-06 |
| 2013-12-31 | $4.58 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |